These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7913705)

  • 1. Multidrug resistance. Clinical opportunities in diagnosis and circumvention.
    Chan HS; DeBoer G; Thorner PS; Haddad G; Gallie BL; Ling V
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):383-410. PubMed ID: 7913705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug resistance in pediatric malignancies.
    Chan HS; DeBoer G; Haddad G; Gallie BL; Ling V
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):275-318. PubMed ID: 7642465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug drug resistance in pediatric sarcomas.
    Chan HS; DeBoer G; Haddad G; Ling V
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):889-908. PubMed ID: 7490247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
    Haddad G; Thorner PS; Bradley G; Dalton WS; Ling V; Chan HS
    Lab Invest; 1994 Oct; 71(4):595-603. PubMed ID: 7967514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
    Kaye SB
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
    Willman CL
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
    Ihnat MA; Lariviere JP; Warren AJ; La Ronde N; Blaxall JR; Pierre KM; Turpie BW; Hamilton JW
    Clin Cancer Res; 1997 Aug; 3(8):1339-46. PubMed ID: 9815817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targets in oncology: implications of the multidrug resistance gene.
    Lum BL; Gosland MP; Kaubisch S; Sikic BI
    Pharmacotherapy; 1993; 13(2):88-109. PubMed ID: 8097038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inability of the mouse mdr2 gene to confer multidrug resistance is linked to reduced drug binding to the protein.
    Buschman E; Gros P
    Cancer Res; 1994 Sep; 54(18):4892-8. PubMed ID: 7915194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance mediated by P-glycoprotein in haematological malignancies.
    Pasman PC; Schouten HC
    Neth J Med; 1993 Jun; 42(5-6):218-31. PubMed ID: 8104318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells.
    Savas B; Cole SP; Akoglu TF; Pross HF
    Nat Immun; 1992; 11(4):177-92. PubMed ID: 1358293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
    Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
    Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
    Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
    Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of multidrug resistance by RU 486.
    Gruol DJ; Zee MC; Trotter J; Bourgeois S
    Cancer Res; 1994 Jun; 54(12):3088-91. PubMed ID: 7911394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulators of multidrug resistance. Preclinical studies.
    Ford JM
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):337-61. PubMed ID: 7642467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
    Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
    J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance in chemotherapy for breast cancer.
    Saeki T; Tsuruo T; Sato W; Nishikawsa K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistance: clinical relevance in acute leukemia.
    List AF
    Oncology (Williston Park); 1993 Oct; 7(10):23-8, 32; discussion 32, 35-8. PubMed ID: 7902728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.